| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/F16H2061-326
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-626
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/F16H61-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/F16H59-105 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32 |
| filingDate |
2002-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae59474fcb4f84e751db5f08299dfe5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6475d58391f4667a347017e40f905838 |
| publicationDate |
2006-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006287509-A1 |
| titleOfInvention |
Novel high affinity human antibodies to tumor antigens |
| abstract |
This invention provides for novel human antibodies that specifically bind to c-erbB-2. The antibodies may be used alone or as components of chimeric molecules that specifically target and deliver effector molecules to cells overexpressing c-erbB-2. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010172868-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8563692-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9139634-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010297076-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009039409-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10975158-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10182984-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3150218-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9534033-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2853267-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8258263-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10822427-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9803021-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10093745-B2 |
| priorityDate |
1995-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |